The preliminary results of a phase II randomized clinical trial of high-dose toremifene chemosensitization in stage IIIB/IV non-small cell lung cancer.
- Author:
Hua CHENG
1
;
Yilong WU
;
Lijia GU
;
Weineng FENG
;
Yimin WENG
;
Chao CHENG
;
Wenzhao ZHONG
;
Shaohong HUANG
Author Information
- Publication Type:Journal Article
- From: Chinese Journal of Lung Cancer 2003;6(5):335-338
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUNDTo investigate whether high-dose toremifene can enhance the efficacy of chemotherapy in non small cell lung cancer.
METHODSUntreated stage IIIB/IV non-small cell lung cancer patients were randomly devided into group A (high-dose toremifene combined with the platinum-based chemotherapy) or group B (the same platinum-based chemotherapy alone).
RESULTSA total of 30 eligible patients had been recruited. Hemotologic and nonhemotologic toxicities were similar with no statistic difference. The median survival for group A was 8 months, 95% CI (6.63-9.37) versus 7.5 months, 95% CI (4.75-10.25) for group B ( P =0.9). One year-survival rate was 31% for group A versus 28% for group B ( P =0.87). The response rate was 25% for group A versus 21% for group B ( P =0.99).
CONCLUSIONSThe results suggest that high-dose toremifene does not enhance the efficacy of platinum-based chemotherapy for IIIB/IV non-small cell lung cancer but toxicities are well tolerated.
